01Core principlesThe concepts and mechanisms needed to understand the subject.
Immunosuppressive therapy is not a single exposure. Glucocorticoids broadly affect innate and adaptive responses; cytotoxic drugs can reduce marrow reserve; calcineurin and other T-cell pathway inhibitors impair cellular defence; B-cell-depleting therapy affects antibody responses; cytokine and kinase inhibitors alter particular signalling networks. Combination therapy reduces redundancy and may create more than additive risk. The expected organisms and duration of vulnerability therefore follow mechanism and pharmacodynamics rather than the label “immunosuppressed.”
Host context modifies risk. Older age, diabetes, lung disease, renal impairment, malnutrition, indwelling devices, previous opportunistic infection, endemic travel and the inflammatory disease itself may be as important as the drug. A patient with structural bronchiectasis and repeated antibiotics has different hazards from a young patient beginning the same agent. Build a baseline infection history from verified episodes, microbiology and imaging and examine skin, mouth, lungs, devices and disease-specific sites before treatment.
Pretreatment work creates a safe starting point. Exclude active infection, update non-live vaccines and consider indicated live vaccines early enough before suppression under current Green Book rules. Perform agent-specific screening for latent tuberculosis, hepatitis B and C, HIV, varicella immunity or other infections only when the pathway requires it. Interpret tests in context: immune suppression can make cellular or antibody tests falsely negative, and a positive marker may represent resolved, latent or active infection requiring specialist classification.
During therapy, infection can be atypical, but the mechanism must be named. Tocilizumab blocks interleukin-6 receptor signalling and its current SmPC warns that acute inflammation and CRP can be muted; corticosteroids may also blunt fever, neutropenia may reduce pus, and T-cell impairment permits viral and fungal reactivation. Ask about exposures and symptoms at each review and teach an urgent access plan. Laboratory monitoring detects cytopenia and organ toxicity but cannot rule out infection. A low CRP should not override new hypoxia, hypotension, confusion or focal symptoms in a high-risk person.
When infection occurs, stabilise and investigate promptly. Obtain cultures and imaging without delaying time-critical antimicrobial therapy, then discuss immunosuppressant management with the prescribing team. Whether to hold a drug depends on infection severity, immune mechanism, half-life, withdrawal or flare risk and the underlying disease. The same applies to restarting. Generic instructions to stop all therapy can precipitate adrenal crisis, transplant rejection or inflammatory flare and are unsafe.
Prevention may include vaccination, exposure avoidance, screening, antimicrobial prophylaxis and immunoglobulin replacement, but each requires a regimen-specific indication. Dose and duration belong to a current specialist protocol considering renal function, interactions, resistance and immune recovery. Monitor adherence and breakthrough infections and reassess need as therapy changes. At transfer, record exact medicine, last dose, expected immune effect, pending results, prophylaxis and named specialist contact.
Key points
- Infection risk is the interaction of immune target, dose and duration, drug combinations, underlying disease, age, comorbidity, previous infection and environmental exposure.
- Before therapy, document infection history and examine for active infection, review vaccination, and complete the exact latent-infection and baseline tests required for that agent and patient.
- Different mechanisms create different patterns: neutropenia, T-cell suppression, B-cell depletion, cytokine blockade and complement inhibition do not confer interchangeable risks.
- Fever and inflammatory markers may be absent or blunted; interleukin-6 receptor blockade with tocilizumab can suppress CRP, so new confusion, hypotension, hypoxia or focal symptoms can be the first infection signal.
- Significant infection requires prompt ABCDE assessment, cultures and treatment through the relevant pathway plus early discussion with the prescribing specialist about holding or modifying therapy.
- Prophylaxis and vaccine timing are indication-specific and change with regimens; never invent a universal antimicrobial dose or interruption interval.
- Risk can persist after the last dose, especially after long-lasting cellular depletion; handover must include the agent, last exposure and recovery plan.
02Mechanisms and patternsImportant relationships and how to distinguish them.
Fever, focal symptoms, unexplained inflammatory change or unresolved antimicrobial therapy should be assessed before initiating or escalating suppression.
Hypotension, confusion, hypoxia, oliguria or rapid functional decline can signal sepsis even without fever or raised CRP.
Tuberculosis, hepatitis B, herpesviruses and endemic fungi emerge according to drug mechanism, prior exposure and geography.
Pneumocystis, invasive fungal, atypical mycobacterial or severe viral disease suggests impaired cellular or combined defence.
Mucosal injury, perianal pain and rapid bacterial or fungal sepsis may occur with few local inflammatory signs.
Recent steroids, prior biologics, low lymphocyte or neutrophil reserve and combination treatment extend risk beyond the current prescription.
Disease flare, drug toxicity, infusion reaction and malignancy can resemble infection, but dangerous infection must be addressed while differentiating.
03Interpreting evidenceInformation, measurements and their limitations.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
Regimen and immune-mechanism map - Why
- Record every immunosuppressive agent, dose, duration, combination, last dose and expected recovery.
- Interpretation and limitations
- Predict which defence is impaired and for how long; product information and specialist protocols determine exact risk management.
- 02
Baseline infection history and examination - Why
- Retrieve serious, recurrent and opportunistic infections, travel, exposures, devices and organ damage.
- Interpretation and limitations
- The same medicine has different absolute risk in different hosts; unresolved active infection usually requires assessment before escalation.
- 03
Agent-specific latent infection screen - Why
- Use the current pathway for tuberculosis, hepatitis, HIV, varicella or other indicated infections.
- Interpretation and limitations
- Negative results can be falsely reassuring during immune suppression; positive results require classification and specialist prevention planning.
- 04
Blood count and organ profile - Why
- Establish marrow, renal and hepatic baseline and monitor at the product-specific frequency.
- Interpretation and limitations
- Cytopenia or organ dysfunction changes infection risk and medicine handling, but normal results do not exclude infection.
- 05
Microbiology and imaging during illness - Why
- Collect site-appropriate cultures and targeted imaging based on syndrome and immune defect.
- Interpretation and limitations
- Seek opportunistic and reactivation diagnoses when the pattern fits, while avoiding delay to sepsis treatment.
- 06
Vaccine and prophylaxis review - Why
- Compare current status with Green Book and the therapy-specific specialist plan.
- Interpretation and limitations
- Specify product, timing, course and owner; live vaccines may be contraindicated and non-live responses may be attenuated.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked caseFever before planned TNF inhibitionAn adult due to start adalimumab, a TNF inhibitor, has weight loss, night sweats and a productive cough after prolonged residence in a high-tuberculosis-incidence country.+
- 1Defer administration pending urgent clinical assessment, examine for active infection and assess physiology; infection symptoms must not be reduced to a screening checkbox.
- 2Recognise epidemiology and symptoms as possible active tuberculosis, separating this from latent infection and inflammatory-disease activity.
- 3Contact the prescribing, respiratory and infection teams, apply respiratory isolation according to local TB policy, obtain a chest X-ray and send three respiratory samples—including an early-morning sample where feasible—for mycobacterial microscopy and culture, adding a rapid molecular test when current NICE NG33 criteria are met rather than relying on one latent-infection test.
- 4Start or resume immunosuppression only through the coordinated specialist plan after classification and treatment decisions, documenting responsibility and verifying follow-up.
02Emergency approachBlunted sepsis presentationA patient receiving prednisolone and tocilizumab is newly confused, hypotensive and hypoxic but afebrile with only modest CRP elevation.+
- 1Treat this as possible sepsis: call for help, assess ABCDE, start monitoring and follow the current emergency pathway without waiting for fever.
- 2Identify immune mechanisms, last doses, prophylaxis, devices and prior resistant organisms while obtaining time-critical cultures and imaging.
- 3Give empiric treatment according to the relevant local immunocompromised-host or sepsis protocol and discuss opportunistic coverage with infection specialists.
- 4Coordinate any immunosuppressant change with the prescribing team, then verify physiological response, microbiology, organ function and an owned restart or recovery plan.
03Safety processPretreatment prevention bundleA patient will begin combination immunosuppression in one month and has fragmented records.+
- 1Reconcile all medicines, prior therapies, serious infections, travel, vaccine records and planned treatment dates across primary and specialist care.
- 2Complete only the agent- and host-specific baseline and latent-infection assessment, recognising false-negative risk and seeking specialist interpretation of discordant results.
- 3Deliver feasible indicated vaccines and any prophylaxis through current protocols, documenting live-vaccine constraints and avoiding unsupervised treatment delay.
- 4Create monitoring, urgent-access and exposure plans with named owners, then verify results, course completion and communication before the first dose.
05Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
- Monitor blood counts and organ function at the agent-specific frequency and act through the current product or specialist threshold.
- At each encounter ask about infection symptoms, exposures, antimicrobial courses, adherence and new combination immunosuppression.
- Track latent-infection treatment, prophylaxis and vaccination courses to completion, including drug interactions and adverse effects.
- After serious infection, document the criteria and responsible specialist for holding, restarting or changing immune therapy.
- Continue risk surveillance for the mechanism-specific period after the last dose; pharmacological clearance may precede immune recovery.
- Review recurrent infections for structural damage, resistance, prophylaxis failure or an additional primary or secondary immune defect.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
Mechanism predicts more than brand
B-cell depletion, TNF blockade and neutropenia create different susceptibilities and vaccine responses even when all are called immunosuppression.
Screening is not clearance
A negative latent-infection test does not exclude active infection and can be falsely negative in severe illness or immune suppression.
CRP depends on signalling
Treatments that interrupt inflammatory pathways can uncouple infection severity from fever or biomarker magnitude.
Drug interruption has hazards
Abrupt steroid withdrawal, transplant rejection and severe disease flare can be more dangerous; coordinate rather than issuing blanket stop advice.
Immune recovery outlasts dosing
Some biologic effects persist for months and can blunt vaccination or permit reactivation after the medicine is no longer on the current list.
Prophylaxis is a prescription
It requires a defined indication, agent, dose, duration, interaction review, adherence plan and stop criterion from current guidance.
Handover needs the last dose
The date and expected immune effect make an apparently historical treatment clinically relevant during acute infection.
07Common pitfallsFrequent interpretation and management errors.
- 01
Treating all immunosuppressants as if they create the same organisms, duration and monitoring needs.
- 02
Starting therapy while symptoms of active infection remain unexplained.
- 03
Interpreting one negative latent-infection test as universal clearance.
- 04
Using absence of fever or low inflammatory markers to exclude severe infection.
- 05
Stopping corticosteroid, transplant or immune therapy abruptly without assessing withdrawal and flare risk with specialists.
- 06
Inventing a prophylaxis dose or vaccine interval instead of using the regimen-specific current pathway.
- 07
Omitting prior biologic exposure and immune-recovery time from acute-care handover.